ABIVAX (ABVX) is trading down at $91.73 (-1.24%), as of the latest quote. It operates in the Health Care sector.
| FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | €12.0M | €4.58M | €4.62M | €12.4M | €4.57M |
| Growth (year over year) | — | −61.7% | +0.8% | +169.4% | −63.3% |
| Operating income | −€41.4M | −€64.8M | −€127.4M | −€173.0M | −€246.1M |
| Operating margin | −346.1% | −1414.7% | −2756.5% | −1389.5% | −5384.2% |
| Net income | −€42.5M | −€60.7M | −€147.7M | −€176.2M | −€336.1M |
| Net margin | −354.9% | −1325.3% | −3197.1% | −1415.7% | −7354.5% |
| EPS (diluted) | −€2.75 | −€3.18 | −€3.43 | −€2.80 | −€4.83 |
| Balance sheet | |||||
| Cash and equivalents | €60.7M | €26.9M | €251.9M | €144.2M | €516.7M |
| Total assets | €109.2M | €75.5M | €327.1M | €205.2M | €584.3M |
| Total liabilities | €83.3M | €68.4M | €131.1M | €164.6M | €129.1M |
| Shareholders' equity | €25.9M | €7.19M | €196.0M | €40.6M | €455.2M |
| Cash flow | |||||
| Operating cash flow | −€45.0M | −€53.9M | −€97.1M | −€154.1M | −€161.1M |
| Capital expenditure | €47.0K | €288.0K | €265.0K | €640.0K | €142.0K |
| Free cash flow | −€45.1M | −€54.2M | −€97.4M | −€154.7M | −€161.3M |
| Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | €1.19M | €5.63M | €1.32M | €4.31M | €994.0K | €1.09M | €2.04M | €440.0K |
| Growth (year over year) | — | — | — | — | −16.2% | −80.6% | +54.3% | −89.8% |
| Operating income | −€44.7M | −€35.3M | −€50.2M | −€42.8M | −€47.2M | −€46.5M | −€80.7M | −€71.6M |
| Operating margin | −3766.5% | −627.7% | −3790.7% | −992.8% | −4748.5% | −4254.0% | −3950.7% | −16283.6% |
| Net income | −€42.9M | −€38.8M | −€55.2M | −€39.4M | −€52.4M | −€48.4M | −€153.4M | −€82.0M |
| Net margin | −3614.4% | −688.9% | −4171.2% | −913.4% | −5268.6% | −4429.5% | −7506.5% | −18627.3% |
| EPS (diluted) | −€0.68 | −€0.62 | −€0.87 | −€0.63 | −€0.83 | −€0.76 | −€2.10 | −€1.14 |
| Balance sheet | ||||||||
| Cash and equivalents | €241.6M | €222.3M | €180.5M | €144.2M | €103.6M | €60.9M | €589.7M | €516.7M |
| Total assets | — | — | — | €205.2M | €166.9M | €119.6M | €652.1M | €584.3M |
| Total liabilities | — | — | — | €164.6M | €173.5M | €167.9M | €140.8M | €129.1M |
| Shareholders' equity | €158.9M | €126.5M | €75.9M | €40.6M | −€6.59M | −€48.3M | €511.2M | €455.2M |
| Cash flow | ||||||||
| Operating cash flow | −€34.8M | −€50.4M | −€35.4M | −€33.5M | −€33.3M | −€33.3M | −€71.3M | −€23.2M |
| Capital expenditure | €12.0K | €224.0K | €311.0K | €93.0K | €44.0K | €19.0K | −€8.00K | €87.0K |
| Free cash flow | −€34.8M | −€50.6M | −€35.7M | −€33.6M | −€33.3M | −€33.4M | −€71.3M | −€23.3M |
From ABIVAX's 20-F and 6-K filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Amounts are in Euro (EUR), as reported, not converted to dollars. Per-share figures are per ordinary share, which is not always the share traded in the US: an ADS can stand for several, or for part of one. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
No recent news mentioning ABIVAX in our feed yet.